Details for New Drug Application (NDA): 204042
✉ Email this page to a colleague
NDA 204042 describes INVOKANA, which is a drug marketed by Janssen Pharms and is included in one NDA. It is available from three suppliers. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the INVOKANA profile page.
The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.
The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.
Summary for 204042
| Tradename: | INVOKANA |
| Applicant: | Janssen Pharms |
| Ingredient: | canagliflozin |
| Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 204042
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 204042
| Mechanism of Action | P-Glycoprotein Inhibitors Sodium-Glucose Transporter 2 Inhibitors |
Medical Subject Heading (MeSH) Categories for 204042
Suppliers and Packaging for NDA: 204042
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| INVOKANA | canagliflozin | TABLET;ORAL | 204042 | NDA | A-S Medication Solutions | 50090-4364 | 50090-4364-0 | 90 TABLET, FILM COATED in 1 BOTTLE (50090-4364-0) |
| INVOKANA | canagliflozin | TABLET;ORAL | 204042 | NDA | A-S Medication Solutions | 50090-5029 | 50090-5029-0 | 90 TABLET, FILM COATED in 1 BOTTLE (50090-5029-0) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Mar 29, 2013 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Sign Up | Patent Expiration: | May 11, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | May 11, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | May 11, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY | ||||||||
Complete Access Available with Subscription
